Form 4: Upstream Bio CFO/COO Granted Equity Awards

Upstream Bio's CFO and COO, Michael Gray, was granted 30,500 restricted stock units and options to purchase 91,500 shares of common stock.

Summary

• Michael Gray, CFO and COO of Upstream Bio, Inc. (UPB), was granted equity awards on January 2, 2026.
• The awards include 30,500 Restricted Stock Units (RSUs) and stock options to purchase 91,500 shares of common stock.
• The RSUs were granted under the Issuer's 2024 Stock Option and Incentive Plan and will vest in sixteen equal quarterly installments following January 1, 2026, subject to continued service.
• The stock options have an exercise price of $27.07 per share and will vest in forty-eight equal monthly installments following January 1, 2026, expiring on January 1, 2036.
• Both awards are subject to Mr. Gray's continued service with the company.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is generally positive for aligning management incentives with shareholder interests and retaining talent. However, it also introduces potential future dilution.

Positives

• Granting of significant equity awards to a key executive (CFO and COO) indicates management retention and alignment of interests with shareholders.
• The awards are performance-based, vesting over several years, which incentivizes long-term commitment and performance.

Negatives

• Dilution risk from the issuance of new shares upon RSU vesting and option exercise, though this is standard for equity compensation plans.

Risks

• Dilution of existing shareholder value upon the vesting and exercise of RSUs and stock options.
• Risk of executive departure before full vesting, leading to forfeiture of unvested awards.

Future Outlook

The vesting schedules for both the RSUs (sixteen equal quarterly installments following January 1, 2026) and stock options (forty-eight equal monthly installments following January 1, 2026) indicate a long-term incentive structure designed to retain the CFO and COO and align their interests with the company's future performance over several years.

Industry Context

Equity compensation, particularly through RSUs and stock options, is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate key executives. The vesting schedules are typical for long-term incentive plans, aiming to align executive performance with shareholder value creation over several years.

Comparison to Industry Standards

• The use of RSUs and stock options for executive compensation is a common practice across the biotech industry, comparable to compensation structures at companies like Moderna, BioNTech, or Amgen, which frequently utilize similar long-term incentive plans to retain talent.
• The vesting periods (4 years for options, 4 years for RSUs) are standard for executive equity grants, aligning with typical industry benchmarks for incentivizing sustained performance and retention.
• An exercise price of $27.07 for stock options is set at or above the market price on the grant date, a common practice to ensure options have value only if the stock price appreciates, similar to grants observed at peer companies.

Related Party Transactions

• The grant of Restricted Stock Units and stock options to Michael Gray, a key executive, constitutes a related party transaction as part of his compensation package.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of awards; improved alignment of executive incentives with long-term shareholder value.
• Employees: May signal a stable and rewarding environment for key personnel, potentially boosting morale.
• Management: Provides significant long-term incentive and compensation tied to company performance.

Next Steps

• Continued service of Michael Gray to ensure vesting of equity awards.
• Future disclosures of any subsequent transactions by Michael Gray.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a key executive, Michael Gray (CFO and COO). While it aligns management incentives with long-term shareholder value and aids in executive retention, it does not present new information that would fundamentally alter the investment thesis for Upstream Bio. The potential for future dilution is a standard consideration for companies utilizing equity compensation. Therefore, a "hold" recommendation is appropriate as this filing alone does not provide a strong catalyst for a "buy" or "sell" decision, but rather confirms ongoing executive compensation practices.

Keywords

Upstream Bio, UPB, Michael Gray, CFO, COO, SEC Form 4, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Executive Compensation, Vesting Schedule